ASCO 2020：11项中华人民共和国研究入选口头报告，17项Poster报告

受全球一新冠霍乱影响，原定于5月29日~6月2日在芝加哥参加的美国流行病学学不会（ASCO）学术内阁不会议今年将首次以线或上形式合办，这是现阶段最大规模的线或上盛不会。现今，内阁不会议的内容可作文公告，共103个sessions，欧美共有11项研究课题表现出色口头报告，17项表现出色Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或拉帕替尼加卡培他滨用于HER2+移到普遍性乳腺胃癌（PHOEBE）：一项III期随机次测试。

大舞台：移到普遍性乳腺胃癌

原作者：欧美医学科学院病房徐兵河副教授、马飞副教授，复旦大学附属病房胡夕春副教授等

内容可号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三中普遍性乳腺胃癌标准治疗法后卡培他滨维持节拍低剂量的III期次测试（SYSUCC-001）。

大舞台：乳腺胃癌—角化/地区/基本功能治疗法

原作者：湖南大学防治当中心地带王树森副教授等

内容可号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

来进行移到普遍性脑的遗传基因特征来数据分析脑脊液当中反向DNA监测的概率: 一新来进行对抗据说对手

大舞台：一新来进行解决问题据说问题

原作者：李美芹 李德兰等

内容可号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

利诺非尼对科特迪瓦拉非尼作为晚期脂质胃癌的一线或治疗法：一项封闭标识、随机、多当中心地带II/III期次测试。

大舞台：小肠肠道胃癌—小肠食管、十二指肠和肺胆

原作者：四川大学华西病房毕锋副教授、欧美老百姓解放军上海浦东病房秦叔逵副教授等

内容可号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

欧美晚期肺胃癌病变阿帕替尼二线或治疗法：一项随机、阿司匹林相比较、双盲III期研究课题

大舞台：小肠肠道胃癌—小肠食管、十二指肠和肺胆

原作者：欧美老百姓解放军上海浦东病房秦叔逵副教授、四川大学华西病房李秋副教授等

内容可号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

晚期患上普遍性卵巢胃癌二次线或粒体减灭术的一项随机III期次测试：SOC1 / SGOG-OV2。

为题：护理人员胃白血病

原作者：复旦大学附属当中山病房臧荣余副教授等

内容可：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈胃癌根治普遍性子宫切除术后基本功能治疗法当中的序贯放低剂量对比原则上放疗或同步放低剂量（STARS研究课题）：一项随机、相比较、封闭标识的III期次测试。

内阁不会议：护理人员胃白血病

原作者：湖南大学防治当中心地带黄鹤副教授、刘继红副教授等

内容可号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：基本功能吉非替尼对比低剂量用于可切除的EGFR凋亡的N1-N2期NSCLC-随机III期流行病学次测试的就此上都存活深入研究。

为题：肺胃癌—非小线或粒体角化-地区/小线或粒体/其他胸部

原作者：江门市老百姓病房吴一龙副教授等

内容可号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR凋亡寡移到非小线或粒体肺胃癌病变一线或酪氨酸腺苷抑制剂联合行动或不联合行动不遗余力前线或角化放疗：III期封闭标识流行病学随机次测试（SINDAS）的当中期结果（NCT02893332）。

为题：肺胃癌-非小线或粒体移到

原作者：广元市老百姓病房曾铭副教授等

内容可：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序普遍性死亡-1（PD-1）的人源化IgG4化学疗法联合行动阿昔替尼用于移到普遍性皮肤卵巢癌病变的Ib期研究课题的总存活期和生物标志物深入研究。

为题：卵巢癌/皮肤胃癌

原作者：北京大学病房郭军、盛锡楠副教授等

内容可：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的兼容普遍性和结果：通用CAR-T线或粒体首次人体次测试治疗法患上/难治普遍性T线或粒体急普遍性淋巴线或粒体脑胃癌（r/r T-ALL）的兼容普遍性和。内阁不会议：开发当中的治疗法技术-免疫治疗法。原作者：王恰巧等内容可：3013广告：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在晚期食管楔形线或粒体胃癌病变当中的应用领域：一项随机的封闭标识II期次测试（ORIENT-2）。内阁不会议：小肠肠道胃癌-小肠食管胃癌、十二指肠胃癌和肺胆道胃癌原作者：徐建明副教授等内容可：4511广告：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异普遍性CAR-T线或粒体对髓母线或粒体瘤的造成危害普遍性治疗法内阁不会议：当中枢神经系统原作者：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、赵旭东内容可：2522广告。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在晚期错配修复缺陷病变当中的应用领域内阁不会议：开发当中的治疗法学-免疫治疗法原作者：沈琳副教授等内容可：3021广告。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART治疗法患上/难治普遍性ACUTE淋巴线或粒体脑胃癌/淋巴瘤的首例人体流行病学次测试内阁不会议: 开发普遍性治疗法学-免疫治疗法原作者简介：张明志，一新兴镇等内容可：3026广告: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）联合行动应用领域于晚期实体瘤病变的Ib期研究课题内阁不会议：发展普遍性治疗法学--分子结构靶向药品和生物科学原作者：龚继芳，沈琳副教授等内容可：3523广告：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin联合行动紫杉醇和nedaplatin治疗法患上普遍性或移到普遍性食管楔形线或粒体胃癌（ESCC）病变的II期研究课题。内阁不会议：小肠肠道胃癌-小肠食管、十二指肠和肺胆道胃癌的研究课题原作者：王志弱，李玉红，王德申，王凤华，任超，谭琼 王志弱、李玉红、王德深、王凤华、任超、谭琼内容可：4522广告：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.内阁不会议：小肠肠道胃癌-小肠食管胃癌、十二指肠胃癌和肺胃癌的二线或治疗法原作者：宋艳等内容可：4524广告：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种分泌物外体外环RNA特征向量用于初始活检时监测高等级胃癌的分泌物外体外环RNA特征向量：一项多当中心地带的回顾普遍性研究课题内阁不会议：移行生殖系统胃白血病---胃癌、睾丸胃癌和胃癌原作者简介：Liaoyuan Li等内容可：5522广告。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 角化晚期宫颈胃癌并作低剂量后的基本功能低剂量内阁不会议: 护理人员胃白血病原作者简介： 李珉珉等内容可：6031广告：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼治疗法甲状腺髓普遍性胃癌的相关普遍性：基于ALTER01031次测试的深入研究。不会话：外周原作者：天津市病房高明副教授内容可：6526广告。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、个数和年龄对安洛替尼治疗法后病变结局的影响: ALTER01031的亚组深入研究内阁不会议：外周原作者：天津市病房高明副教授内容可：6527广告。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA深入研究数据分析I-IIIA期非小线或粒体肺胃癌（NSCLC）病变术后患上: GASTO1035和GASTO1018的结果内阁不会议：肺胃癌-非小线或粒体角化-地区普遍性/小线或粒体/小线或粒体/其他胸科胃白血病原作者：Si-Yu Wang等内容可：9023广告：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小线或粒体肺胃癌（NSCLC）当中EGFR酪氨酸腺苷抑制剂的一新型耐药选择性内阁不会议:肺胃癌-非小线或粒体移到普遍性肺胃癌原作者简介：赵昕，金艾利，满宇，欧娘子，梅氏，薛武，杨少，范敏 赵昕、金艾利、满宇、欧娘子、梅氏、薛武、杨绍、范敏内容可：9528广告：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1次测试当中晚期卵巢癌总存活的替代终点内阁不会议：卵巢癌/皮肤胃癌原作者：聂润聪，袁书弱，李元芳，陈英波，周志伟 聂润聪、袁书弱、李元芳、陈英波、周志伟内容可：10030广告：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼治疗法患上或移到普遍性原发普遍性恶普遍性骨病变的II期研究课题内阁不会议： 恶普遍性肿瘤原作者：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王琼、蔡启庆、涂崇奇、范正福、杨瑶内容可：11525广告。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 进一步评价安罗替尼在晚期恶普遍性肿瘤病变多线或治疗法当中的兼容普遍性和。内阁不会议：恶普遍性肿瘤原作者：姚伟涛，王家弱，王文，王欣，杜一新辉，田志浩，牛晓颖 姚伟涛、王家弱、王文、王鑫、杜鑫辉、田志超、牛晓英内容可：11526广告：414